Cathy E. Nolan

1.3k total citations
8 papers, 585 citations indexed

About

Cathy E. Nolan is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Cathy E. Nolan has authored 8 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 5 papers in Pathology and Forensic Medicine and 5 papers in Oncology. Recurrent topics in Cathy E. Nolan's work include Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and CAR-T cell therapy research (3 papers). Cathy E. Nolan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and CAR-T cell therapy research (3 papers). Cathy E. Nolan collaborates with scholars based in United States, Australia and Egypt. Cathy E. Nolan's co-authors include Sari H. Enschede, Todd Busman, Rod Humerickhouse, Charles M. Rudin, Leena Gandhi, D. Ross Camidge, Andrew Krivoshik, Philip M. Hemken, Christine L. Hann and Divis Khaira and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Cathy E. Nolan

8 papers receiving 577 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cathy E. Nolan United States	6	384	206	117	113	68	8	585
Scott Ackler United States	8	472 1.2×	233 1.1×	94 0.8×	76 0.7×	75 1.1×	10	625
Elisabeth Walsby United Kingdom	14	308 0.8×	216 1.0×	94 0.8×	131 1.2×	83 1.2×	25	559
Llorenç Coll-Mulet Spain	11	452 1.2×	263 1.3×	67 0.6×	156 1.4×	90 1.3×	12	663
Sandrine Jayne United Kingdom	18	578 1.5×	142 0.7×	156 1.3×	210 1.9×	104 1.5×	37	876
Gary Borzillo United States	12	492 1.3×	169 0.8×	93 0.8×	93 0.8×	147 2.2×	24	737
Andrea Ghelli Luserna di Rorà Italy	13	513 1.3×	303 1.5×	73 0.6×	63 0.6×	76 1.1×	38	735
Cory Mavis United States	16	441 1.1×	285 1.4×	245 2.1×	159 1.4×	120 1.8×	74	754
Moacyr Oliveira United States	4	392 1.0×	237 1.2×	46 0.4×	47 0.4×	64 0.9×	4	593
Silvia L. Locatelli Italy	15	373 1.0×	146 0.7×	134 1.1×	67 0.6×	144 2.1×	42	616
Jianning Yang United States	14	320 0.8×	220 1.1×	237 2.0×	254 2.2×	125 1.8×	29	693

Countries citing papers authored by Cathy E. Nolan

Since Specialization

Citations

This map shows the geographic impact of Cathy E. Nolan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cathy E. Nolan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cathy E. Nolan more than expected).

Fields of papers citing papers by Cathy E. Nolan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cathy E. Nolan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cathy E. Nolan. The network helps show where Cathy E. Nolan may publish in the future.

Co-authorship network of co-authors of Cathy E. Nolan

This figure shows the co-authorship network connecting the top 25 collaborators of Cathy E. Nolan. A scholar is included among the top collaborators of Cathy E. Nolan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cathy E. Nolan. Cathy E. Nolan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Vos, Sven de, L. J. Swinnen, Dee Dee Wang, et al.. (2018). Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Annals of Oncology. 29(9). 1932–1938. 51 indexed citations

Swinnen, L. J., Christopher R. Flowers, Dee Dee Wang, et al.. (2017). VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY. Hematological Oncology. 35(S2). 90–90. 4 indexed citations

Seymour, John F., Matthew S. Davids, John M. Pagel, et al.. (2013). Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). 7018–7018. 20 indexed citations

Davids, Matthew S., John F. Seymour, John F. Gerecitano, et al.. (2013). Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 31(15_suppl). 8520–8520. 10 indexed citations

Seymour, John F., Matthew S. Davids, Mary Ann Anderson, et al.. (2012). The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. Blood. 120(21). 3923–3923. 6 indexed citations

Davids, Matthew S., Andrew W. Roberts, Mary Ann Anderson, et al.. (2012). The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. Blood. 120(21). 304–304. 28 indexed citations

Gandhi, Leena, D. Ross Camidge, Moacyr Oliveira, et al.. (2011). Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. Journal of Clinical Oncology. 29(7). 909–916. 462 indexed citations

Rudin, Charles M., Mafalda Oliveira, Edward B. Garon, et al.. (2010). A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC).. Journal of Clinical Oncology. 28(15_suppl). 7046–7046. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact